1. Home
  2. MBIO vs GLTO Comparison

MBIO vs GLTO Comparison

Compare MBIO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • GLTO
  • Stock Information
  • Founded
  • MBIO 2015
  • GLTO 2011
  • Country
  • MBIO United States
  • GLTO Denmark
  • Employees
  • MBIO N/A
  • GLTO N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBIO Health Care
  • GLTO Health Care
  • Exchange
  • MBIO Nasdaq
  • GLTO Nasdaq
  • Market Cap
  • MBIO 7.3M
  • GLTO 6.5M
  • IPO Year
  • MBIO N/A
  • GLTO 2020
  • Fundamental
  • Price
  • MBIO $2.80
  • GLTO $4.78
  • Analyst Decision
  • MBIO Strong Buy
  • GLTO Buy
  • Analyst Count
  • MBIO 1
  • GLTO 1
  • Target Price
  • MBIO $100.00
  • GLTO $10.00
  • AVG Volume (30 Days)
  • MBIO 405.3K
  • GLTO 21.3K
  • Earning Date
  • MBIO 03-10-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • MBIO N/A
  • GLTO N/A
  • EPS Growth
  • MBIO N/A
  • GLTO N/A
  • EPS
  • MBIO N/A
  • GLTO N/A
  • Revenue
  • MBIO N/A
  • GLTO N/A
  • Revenue This Year
  • MBIO N/A
  • GLTO N/A
  • Revenue Next Year
  • MBIO N/A
  • GLTO N/A
  • P/E Ratio
  • MBIO N/A
  • GLTO N/A
  • Revenue Growth
  • MBIO N/A
  • GLTO N/A
  • 52 Week Low
  • MBIO $2.40
  • GLTO $4.24
  • 52 Week High
  • MBIO $74.50
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 29.74
  • GLTO 45.49
  • Support Level
  • MBIO $2.40
  • GLTO $4.24
  • Resistance Level
  • MBIO $3.04
  • GLTO $4.65
  • Average True Range (ATR)
  • MBIO 0.65
  • GLTO 0.33
  • MACD
  • MBIO 0.06
  • GLTO -0.02
  • Stochastic Oscillator
  • MBIO 9.30
  • GLTO 43.25

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: